Aptose Biosciences (NASDAQ:APTO) Shares Up 5.2%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) shares shot up 5.2% on Wednesday . The company traded as high as $3.05 and last traded at $3.01, 333,686 shares traded hands during mid-day trading. An increase of 2% from the average session volume of 325,830 shares. The stock had previously closed at $2.86.

A number of brokerages have weighed in on APTO. HC Wainwright set a $9.00 price target on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Tuesday, April 2nd. Zacks Investment Research upgraded shares of Gerdau from a “sell” rating to a “hold” rating in a report on Monday, May 13th. Finally, Roth Capital reiterated a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. Seven investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $5.75.

The company’s 50 day simple moving average is $2.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.93 and a current ratio of 5.93. The firm has a market capitalization of $161.33 million, a price-to-earnings ratio of -3.50 and a beta of 1.62.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.03. On average, equities research analysts expect that Aptose Biosciences Inc. will post -0.58 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Geode Capital Management LLC purchased a new position in shares of Aptose Biosciences in the 4th quarter valued at $33,000. Boston Advisors LLC purchased a new position in shares of Aptose Biosciences in the 1st quarter valued at $36,000. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Aptose Biosciences by 37.3% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 21,400 shares during the period. Virtu Financial LLC purchased a new position in shares of Aptose Biosciences in the 1st quarter valued at $198,000. Finally, Sanders Morris Harris LLC purchased a new position in shares of Aptose Biosciences in the 2nd quarter valued at $572,000. 5.94% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile (NASDAQ:APTO)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Article: What is a front-end load?

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.